Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30696931 | 0.89 | RAB9A (0.45) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL8573566 | 0.83 | RAB9A (0.50) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL23970519 | 0.83 | ALDH1A1 (0.50) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL15273679 | 0.82 | LMNA (0.50) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL13126573 | 0.81 | LMNA (0.47) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL4701434 | 0.81 | RAB9A (0.49) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL1458129 | 0.81 | ALDH1A1 (0.50) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL1406834 | 0.81 | NPC1 (0.49) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL26654708 | 0.81 | CYP1A2 (0.49) | RAB9ANPC1KDM4EALDH1A1HPGD | |
| SCHEMBL2672130 | 0.81 | RAB9A (0.46) | RAB9ANPC1KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720060-A1 | PRMT5 INHIBITORS | Ryvu Therapeutics S.A. (PL) | 2026-04-08 | — | — | EP | disclosed |
| US-12485144-B2 | 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof | NURIX THERAPEUTICS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250263399-A1 | CBL-B MODULATORS AND USES THEREOF | SCHRÖDINGER, INC. | 2025-08-21 | — | — | US | disclosed |
| EP-4602028-A1 | CBL-B MODULATORS AND USES THEREOF | Nimbus Clio, Inc. (US) | 2025-08-20 | — | — | EP | disclosed |
| US-12325697-B2 | CBL-B modulators and uses thereof | NIMBUS CLIO, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| US-20250163038-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. | 2025-05-22 | — | — | US | disclosed |
| CN-114364667-B | 3-Substituted piperidines for Cbl-b inhibition and use of Cbl-b inhibitors in combination with cancer vaccines and/or oncolytic viruses | 紐力克斯治疗公司 | 2025-01-10 | — | — | CN | disclosed |
| WO-2024240894-A1 | PRMT5 INHIBITORS | Ryvu Therapeutics S.A. (PL) | 2024-11-28 | — | — | WO | disclosed |
| CN-118791465-A | Cbl-b inhibitors | 北京诺诚健华医药科技有限公司 | 2024-10-18 | — | — | CN | disclosed |
| WO-2024212941-A1 | CBL-B INHIBITOR | 北京诺诚健华医药科技有限公司 | 2024-10-17 | — | — | WO | disclosed |
| US-8598155-B2 | Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders | PFIZER INC. (US) | 2013-12-03 | — | — | US | disclosed |
| WO-2012168817-A1 | PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE2 INHIBITORS AND/OR CYP3A4 INHIBITORS | PFIZER INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20120214791-A1 | Imidazo[5,1-f][1,2,4]Triazines for the Treatment of Neurological Disorders | PFIZER INC. | 2012-08-23 | — | — | US | disclosed |
| EP-1928840-B1 | 1H-Pyrazole-4-carboxamides, their preparation and their use as 11-beta-hydroxysteroid dehydrogenase inhibitors | HOFFMANN LA ROCHE (CH) | 2011-08-10 | — | — | EP | disclosed |
| EP-1928840-A1 | 1H-PYRAZOLE 4-CARBOXYLAMIDES, THEIR PREPARATION AND THEIR USE AS 11BETA-HYDROXYSTEROID DEHYDROGENASE | F. Hoffmann-Roche AG (CH) | 2008-06-11 | — | — | EP | disclosed |
| US-7345058-B2 | (1-Methyl-5-phenyl-1H-pyrazol-4-yl)-(trans-octahydro-isoquinolin-2-yl)methanone; 11 beta -hydroxysteroid dehydrogenase inhibitor; upregulation of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase); antidiabetic agent; type II diabetes mellitus and metabolic syndrome | HOFFMANN-LA ROCHE INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345058-B2 | (1-Methyl-5-phenyl-1H-pyrazol-4-yl)-(trans-octahydro-isoquinolin-2-yl)methanone; 11 beta -hydroxysteroid dehydrogenase inhibitor; upregulation of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase); antidiabetic agent; type II diabetes mellitus and metabolic syndrome | HOFFMANN-LA ROCHE INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-7345058-B2 | (1-Methyl-5-phenyl-1H-pyrazol-4-yl)-(trans-octahydro-isoquinolin-2-yl)methanone; 11 beta -hydroxysteroid dehydrogenase inhibitor; upregulation of phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase); antidiabetic agent; type II diabetes mellitus and metabolic syndrome | HOFFMANN-LA ROCHE INC. (US) | 2008-03-18 | — | — | US | disclosed |
| WO-2006106052-A1 | PYRAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-12 | — | — | WO | disclosed |
| US-20060223852-A1 | Pyrazoles | GILLESPIE PAUL | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163038-A1 | CBL-B MODULATORS AND USES THEREOF | CBLB, CBL, CBLC | RAB9A 2454/4885NPC1 3294/4885KDM4E 623/4885 |
| US-12485144-B2 | 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof | CBLB, CBL, CBLC | RAB9A 862/4885NPC1 2987/4885KDM4E 317/4885 |
| US-20060223852-A1 | Pyrazoles | GPR119, PDK2, PC | RAB9A 1873/4885NPC1 889/4885KDM4E 4119/4885 |
| US-20250263399-A1 | CBL-B MODULATORS AND USES THEREOF | CBLB, CBL, CBLC | RAB9A 1825/4885NPC1 1290/4885KDM4E 787/4885 |
| US-12325697-B2 | CBL-B modulators and uses thereof | CBLB, CBL, CBLC | RAB9A 1825/4885NPC1 1290/4885KDM4E 787/4885 |
| US-20120214791-A1 | Imidazo[5,1-f][1,2,4]Triazines for the Treatment of Neurological Disorders | GRIK5, GRIN2C, BDNF | RAB9A 2327/4885NPC1 463/4885KDM4E 3588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.